Exelixis granted Merck exclusive, worldwide rights to its preclinical phosphoinositide 3-kinase (PI3K) delta program, including lead inhibitor XL499 and related compounds

Exelixis Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$633.5m on 12/30/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Merck & Co. Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced